MANSFIELD, Mass., Aug. 23, 2011 /PRNewswire/ — PrimeraDx today
announced the launch of the ICEPlex® system, the only
instrument on the market used for simultaneous detection and
quantification of disparate target types, such as mRNA, miRNA, SNPs
and DNA
“We are excited to have launched the ICEPlex, a
quantitative multiplex PCR platform,” stated President and
CEO Matthew McManus, MD, PhD. “No longer will users
have to rely on semi-quantitative multiplex solutions. The
ability to take one slice of tissue, extract the nucleic acids, and
in one well, in parallel, look at mRNA expression, microRNA
expression and SNPs is very powerful.”
PrimeraDx has developed an open platform enabling clinical labs
to easily develop cost-effective, high impact molecular diagnostic
tests. The ICEPlex instrument has already been placed
with a number of key accounts, including large academic research
centers, reference laboratories and bio-pharmaceutical companies.
The ICEPlex instrument has a simple workflow and
comes with on-board software for assay design, data analysis and
reporting.
“It is very exciting to have this innovative platform from
PrimeraDx. As far as I know, this is the only platform that
allows you to assay multiple target types, like mRNA, miRNA and
SNPs, in a single well,” commented Andrew Schade, MD, PhD,
Senior Director of Lilly Clinical Diagnostics Laboratory.
“The ICEPlex system is already changing the way
we approach assay development, allowing us to create innovative
solutions that were previously not possible.”
About PrimeraDx
PrimeraDx is dedicated to the high growth field of molecular
diagnostics. The Company has developed a unique platform for
high-multiplex, quantitative, real-time PCR based on its
proprietary STAR technology, implemented on the walk-away
ICEPlex instrument syst
‘/>”/>